2026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
Batool Abuhalimeh, Vascular Medicine Consultant at Cleveland Clinic AbuDhabi, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in American College of Cardiology, adding:
”Risk factor modification remains the cornerstone of vascular care, and effective lipid management is one of the most powerful tools we have to reduce cardiovascular and limb events. As the evidence continues to evolve, staying current with guideline-directed therapy is essential for optimizing outcomes in our patients.
I’m excited to share our American College of Cardiology expert analysis of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, highlighting the updates that matter most for vascular specialists,from LDL-C targets and nonstatin therapies to practical implementation in everyday clinical practice.
Take a look and let us know your thoughts.”
Title: Implications of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline for Lipid Management in Vascular Disease
Authors: Batool Jamal Abuhalimeh, Musa’ab Alhmouz, Leili Behrooz
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists
-
Aug 21, 2026, 13:51Join EHC 2026 Annual Conference
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia